Advertisement
Organisation › Details
Medicxi III fund
In July 2019 Medicxi announces the closing of Medicxi III, a new €400 million fund. This brings the total amount raised by Medicxi in the last three years to over $1 billion. From this single fund, Medicxi will invest in early and late stage biopharma companies across the full healthcare continuum from discovery to late stage clinical assets. Cornerstone strategic investors in Medicxi III are Novartis and Johnson & Johnson Innovation - JJDC, Inc. (JJDC), both of whom have backed Medicxi in earlier funds. The fund also includes all of the institutional limited partners that previously invested in Medicxi's funds, as well as several new investors, including established hospital foundations and medical institutions. Medicxi III will be supported by the Medicxi Scientific Advisory Board, which benefits from the scientific and commercial expertise of senior executives from Novartis, the Janssen Pharmaceutical Companies of Johnson & Johnson, GlaxoSmithKline and Verily (an Alphabet company). The new fund will continue to focus on Medicxi's pioneering 'asset-centric' investment model as well as investing in fully integrated private companies with an underlying platform and/or a pipeline of assets that Medicxi believes can deliver licensed pharmaceutical products to satisfy unmet medical needs. The size of the fund and the speed with which it was closed reflects the continued maturity of the life sciences sector across Europe, with investors now prioritizing their attention and support for emerging biopharma companies and their efforts to translate breakthrough science into pipelines of new drugs. *
Start | 2019-07-19 closing | |
Group | Medicxi Ventures (formerly Index Ventures Life Sciences) | |
Industry | Medicxi III fund | |
Industry 2 | LIFE SCIENCES | |
Person | de Rubertis, Francesco (Medecxi Ventures 201602 General Partner before Index Ventures 200708 General Partner) | |
Region | London, Greater London | |
Country | United Kingdom (GB) | |
Street | 3 Burlington Gardens | |
City | W1S 3EP London | |
Tel | +44-20-7154-2020 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Medicxi Ventures. (7/19/19). "Press Release: Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters". London, Geneva & Jersey. | ||
Record changed: 2020-08-04 |
Advertisement
More documents for Medicxi Ventures (formerly Index Ventures Life Sciences)
- [1] Medicxi Ventures. (7/19/19). "Press Release: Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters". London, Geneva & Jersey....
- [2] Xenikos B.V.. (5/15/18). "Press Release: Dutch Company Xenikos Secures USD 30 Million in Series B Financing". Nijmegen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top